CoronaVac vaccine, developed by the Chinese laboratory Sinovac and produced in Brazil by the Butantan Institute, is safe and has a 50.7% efficiency in the protection of symptomatic COVID-19 cases. For moderate cases (which require medical attention), the protection is 83.7%.
The data are from a study published this Sunday (11) on the results of the trial carried out by Butantan.
Another finding is that the CoronaVac vaccine is more efficient if given with a longer interval between the two shots. If the second dose is given 21 days or more after the first, the efficiency of the vaccine reaches 62%.
CoronaVac vaccine is now administered in more than 30 countries.
Brazil has already vaccinated 23,077,025 people with the first dose, which represents 14.3% of the adult population. The second shot was applied to 6,978,834 people. The data is from the consortium formed by the newspapers Folha de S. Paulo, UOL, O Estado de S. Paulo, Extra, O Globo and G1.